Cytoband (human 10q23.2 SNCG) & (mouse 14qB Sncg).
Here I present: “γ-Synuclein: Breast Cancer-specific“, Victor McKusick, Mendelian Inheritance in Man’, 1966. (SNCG) icd10= C50.919
γ-Synuclein (SNCG) Breast Cancer Specificity.
γ-Synuclein (SNCG) is a small (~127 aa) cytosolic protein of the synuclein family (α, β, γ).
Unlike α-synuclein (neuronal, Parkinson disease–related), γ-synuclein is minimally expressed in most normal adult tissues, including normal breast epithelium.
Why it is Considered Breast Cancer–specific.
Aberrant overexpression of γ-synuclein is seen in a high proportion of breast carcinomas, while it is absent or very low in normal breast tissue.
Early transcriptomic and immunohistochemical studies showed tumor-restricted activation of SNCG in breast cancer, supporting its use as a tumor marker rather than a lineage marker.
Clinical and Biological Significance.
Association with aggressive disease.
Overexpression correlates with:
Higher tumor grade.
Increased invasion and metastasis.
Poorer prognosis in several cohorts.
Mechanistic roles.
γ-Synuclein has been implicated in:
Enhanced cell motility and invasion.
Modulation of ER (estrogen receptor) signaling.
Interference with cell-cycle control and stress responses.
Chemoresistance (reported for agents like taxanes and anthracyclines in some models).
Biomarker Potential.
Diagnostic:
Helps distinguish malignant from benign/normal breast tissue when used in panels.
Prognostic:
Higher expression often predicts worse outcomes.
Predictive:
Possible indicator of response to endocrine therapy or chemotherapy (still under validation).
Specificity Caveat.
While often described as “breast cancer–specific,” γ-synuclein is not exclusive to breast cancer:
It is also overexpressed in ovarian, colon, liver, pancreatic, and some lung cancers.
The key point is cancer-specific overexpression, not absolute tissue exclusivity.
Therapeutic Implications.
No approved therapies directly target γ-synuclein yet.
Ongoing Interest Focuses:
Downregulating SNCG expression.
Disrupting γ-synuclein–mediated signaling pathways.
Using it as a stratification marker in clinical trials.
One-Line Summary.
γ-Synuclein is a normally silent protein in breast tissue that becomes aberrantly activated in breast cancer, where its expression marks aggressive behavior and holds promise as a diagnostic and prognostic biomarker—though it is not unique to breast cancer alone.
There is evidence that the γ-synuclein: breast cancer-specific gene (SNCG) is encoded on genomic coordinate 10:86,955,759 and cytoband 10q23.2 in humans.
